Sagar Lonial, MD, FACP

Articles

Dr Lonial on the Outcomes of the IKEMA Trial in Relapsed Multiple Myeloma

October 3rd 2023

Sagar Lonial, MD, FACP, discusses the final overall survival analysis of the phase 3 IKEMA trial of isatuximab when combined with carfilzomib and dexamethasone in patients with relapsed multiple myeloma, highlighting the progression-free survival and OS outcomes.

CAR T-Cell Therapy for RRMM

March 21st 2022

Implications for treating patients with relapsed/refractory multiple myeloma with CAR T cells vs antibody-drug conjugates.

Treatment of Keratopathy Associated with Belantamab Mafodotin

March 21st 2022

Recommendations for managing ocular toxicities associated with belantamab mafodotin when used as treatment for relapsed/refractory multiple myeloma.

Unmet Needs in the Management of Multiple Myeloma

March 11th 2022

Sagar Lonial, MD, provides insight on mechanisms of resistance to CAR T-cell therapies, and the panel shares unmet needs and future directions for the treatment of multiple myeloma.

Role of CAR T Therapies in Newly Diagnosed Multiple Myeloma

March 11th 2022

Ola Landgren, MD, PhD, leads the discussion on the use of cilta-cel and ide-cel in newly diagnosed multiple myeloma and the sequencing of available therapies in transplant-eligible and transplant-ineligible patients.

Novel CAR-T Therapies in Relapsed/Refractory MM and Identifying the Right Patients for CAR-T Therapies

March 11th 2022

Experts discuss emerging BCMA-targeting CAR T-cell therapies under investigation for treating multiple myeloma and barriers to CAR T access.

KarMMa Study in Relapsed/Refractory Multiple Myeloma

March 4th 2022

Katja Weisel, MD, reviews the study results from the KarMMa study evaluating the use of ide-cel in patients with relapsed/refractory multiple myeloma.

CARTITUDE-1 Study in Relapsed/Refractory Multiple Myeloma

March 4th 2022

Ola Landgren, MD, PhD, leads a review of the updated efficacy and safety results and subgroup analysis of the CARTITUDE-1 study for patients with relapsed/refractory multiple myeloma.

BCMA-Targeting Belantamab Mafodotin: Role in the Treatment Landscape of RRMM

February 28th 2022

The rationale for treating relapsed/refractory multiple myeloma with belantamab mafodotin, and studies investigating the drug’s potential in earlier treatment settings.

Treatment Approach for a 57-Year-Old Man With Triple-Class Refractory MM

February 28th 2022

Sagar Lonial, MD, FACP, highlights a novel treatment option available for a 57-year-old man whose disease progresses after 3 prior lines of therapy, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.

Clinical Case 3: A 56-Year-Old Man With Multiple Myeloma

February 25th 2022

Expert hematologist-oncologists review the case of a 56-year-old man with multiple myeloma who received CAR T-cell therapy and share their approaches to treatment.

Treatment Options for Patients Progressing on Belantamab Mafodotin in MM

February 25th 2022

Katja Weisel, MD, reviews potential mechanisms of resistance to belantamab mafodotin in patients with multiple myeloma, and Sagar Lonial, MD, FACP, discusses potential treatment options for patients who progress on belantamab mafodotin.

Ongoing Trials of Belantamab Mafodotin in MM and Optimal Position in Treatment Landscape

February 18th 2022

Joshua Richter, MD, and Sagar Lonial, MD, FACP, review key ongoing clinical trials with belantamab mafodotin in patients with multiple myeloma and the optimal position for belantamab mafodotin in the myeloma treatment landscape.

Managing AEs With Belantamab Mafodotin in Relapsed/Refractory Myeloma

February 18th 2022

Katja Weisel, MD, shares recommended strategies for the prevention and management of potential ocular effects of belantamab mafodotin in multiple myeloma.

Updates From ASH 2021 for Belantamab-based Combinations in Myeloma

February 11th 2022

Ola Landgren, MD, PhD, and Joshua Richter, MD, review belantamab mafodotin–based combination regimens currently being evaluated in relapsed/refractory multiple myeloma, as well as the newly diagnosed setting, as presented at the recent ASH 2021 meeting.

Role of Belantamab Mafodotin in R/R MM

February 11th 2022

Sagar Lonial, MD, reviews key takeaways from the DREAMM-2 trial, and Katja Weisel, MD, comments on the potential use of belantamab mafodotin in the early relapse setting for multiple myeloma.

Clinical Case 2: 59-Year-Old Woman With R/R MM

February 4th 2022

Experts in hematology-oncology review the case of a 59-year-old woman with relapsed/refractory multiple myeloma and discuss their thoughts on the given treatment approach.

Selecting the Appropriate Treatment Regimen and Assessing Response at First Relapse in Myeloma

February 4th 2022

Sagar Lonial, MD; Joshua Richter, MD; and Ola Landgren, MD, PhD, comment on the selection of the appropriate treatment regimen at first relapse, including CD38-based, non-CD38–based and non-PI–based treatment regimens for multiple myeloma, and discuss their approach to assessing treatment response.

IKEMA Study in R/R Multiple Myeloma

January 28th 2022

Ola Landgren, MD, PhD, reviews the results and clinical implications of the IKEMA study for patients with relapsed/refractory multiple myeloma.

Updates From the CANDOR Study in R/R Multiple Myeloma

January 28th 2022

Katja Weisel, MD, leads a review of the study design and updated efficacy and safety results of the phase 3 CANDOR study for patients with relapsed/refractory multiple myeloma.